Revvity, Inc. (NYSE: RVTY) reported fourth-quarter results that exceeded analyst expectations on both earnings and revenue, but shares fell more than 4% intraday following the release.

Adjusted earnings per share came in at $1.70, beating the consensus estimate of $1.55. Revenue totaled $772.06 million, surpassing analyst expectations of $758.53 million.

Quarterly revenue increased 6% from $729 million a year earlier, with organic growth of 4%. GAAP earnings per share rose to $0.87 from $0.78 in the prior-year period.

The Diagnostics segment led performance, posting a 10% increase in revenue to $390 million, including 7% organic growth. Life Sciences revenue increased 2% to $382 million, though organic revenue for the segment was flat year over year.

For full-year 2025, Revvity reported adjusted earnings per share of $5.06, up from $4.90 in 2024, while total revenue rose to $2.86 billion from $2.76 billion.

Looking ahead, the company initiated fiscal 2026 guidance, projecting revenue of $2.96 billion to $2.99 billion, above the $2.94 billion consensus estimate. Adjusted earnings per share were forecast at $5.35 to $5.45, also exceeding analyst expectations of $5.32.